Difference between revisions of "Muscularis propria invasion in the urinary bladder"

Jump to navigation Jump to search
 
(2 intermediate revisions by the same user not shown)
Line 8: Line 8:
Staging of bladder cancer is dealt with in the ''[[bladder cancer staging]]'' article.
Staging of bladder cancer is dealt with in the ''[[bladder cancer staging]]'' article.


'''''Muscle invasive bladder cancer''''' redirects to this article and refers to invasion of the ''muscularis propria''.
'''''Muscle invasive bladder cancer''''' redirects to this article and refers to invasion of the ''muscularis propria''
 
''Bladder muscularis propria invasion'' and ''urinary bladder muscularis propria invasion'' redirect to this article.


==General==
==General==
Line 69: Line 71:
Image: Muscle invasive urothelial carcinoma -- high mag.jpg | MIUC - high mag.
Image: Muscle invasive urothelial carcinoma -- high mag.jpg | MIUC - high mag.
</gallery>
</gallery>
==IHC==
''Smoothelin'' [[immunostain]]:<ref name=pmid18936687>{{Cite journal  | last1 = Paner | first1 = GP. | last2 = Shen | first2 = SS. | last3 = Lapetino | first3 = S. | last4 = Venkataraman | first4 = G. | last5 = Barkan | first5 = GA. | last6 = Quek | first6 = ML. | last7 = Ro | first7 = JY. | last8 = Amin | first8 = MB. | title = Diagnostic utility of antibody to smoothelin in the distinction of muscularis propria from muscularis mucosae of the urinary bladder: a potential ancillary tool in the pathologic staging of invasive urothelial carcinoma. | journal = Am J Surg Pathol | volume = 33 | issue = 1 | pages = 91-8 | month = Jan | year = 2009 | doi = 10.1097/PAS.0b013e3181804727 | PMID = 18936687 }}</ref>
*Muscularis propria - usu. strong. †
*Muscularis mucosae - negative/weak. †
Note:
*† Overlap between the patterns is described;<ref name=pmid20154589>{{Cite journal  | last1 = Miyamoto | first1 = H. | last2 = Sharma | first2 = RB. | last3 = Illei | first3 = PB. | last4 = Epstein | first4 = JI. | title = Pitfalls in the use of smoothelin to identify muscularis propria invasion by urothelial carcinoma. | journal = Am J Surg Pathol | volume = 34 | issue = 3 | pages = 418-22 | month = Mar | year = 2010 | doi = 10.1097/PAS.0b013e3181ce5066 | PMID = 20154589 }}</ref> this limits the utility of the immunostain.
**Immunostain '''not''' used in many practice environments.


==Sign out==
==Sign out==
48,584

edits

Navigation menu